|作者：||Zhang Bin, Wang Di, Zhang Xia, Cui Xiaonan, Kong Li, Li Minghuan, Yu Jinming|
1Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.
2Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
3Department of Oncology, The Fifth People's Hospital of Dalian, Dalian, People's Republic of China.
4Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Repu
|刊名：||OncoTargets and therapy, 2019, Vol.12 , pp.9663-9668|
|关键词：||Case report; Lung cancer; Mixed neuroendocrine carcinoma; Poor tolerance; Review; Temozolomide;|
|原始语种摘要：||The incidence of lung neuroendocrine carcinomas, which originate from lung neuroendocrine cells, is 1.35/100,000, among which mixed neuroendocrine carcinomas are very rare. Because of the heterogeneity and significant differences in sensitivity to treatments, there is no effective treatment, and the prognosis is poor. In this article, we report the diagnosis and treatment of a case of mixed neuroendocrine carcinoma of the lung in our hospital. During the treatment, the patients had significant myelosuppression after initial chemotherapy, but benefited from oral chemotherapy consisting of a combination of capecitabine and temozolomide (CAPTEM). The report was approved by the affiliated Cancer Hospital of Shandong University.|